FENOGAL Capsule, Hard

Fenofibrate

200 mg

BENSON PHARMACEUTICALS

Pack size	30's Pack
Dispensing mode
Source
Agent
Retail Price	1.05 AED

Indications

FENOGAL Capsule, Hard is used for: Hyperlipidemia, Hypercholesterolaemia, Hypertriglyceridaemia

Adult Dose

Oral Hypercholesterolemia, Mixed dyslipidemia, Hypertriglyceridemia Tablet: 40-160mg once daily. Capsule: 200mg once daily. Hepatic impairment: Contraindicated.

Child Dose

Safety and efficacy not established

Renal Dose

Renal impairment Mild-Moderate: Initial: lower dose Severe: contraindicated

Administration

Should be taken with food.

Contra Indications

Hypersensitivity; severe hepatic and renal impairment. Unexplained persistent liver function abnormality and primary biliary cirrhosis; preexisting gall bladder disease. Pregnancy, lactation.

Precautions

Renal or hepatic impairment. Monitor LFTs and blood counts regularly. Increased risk of cholelithiasis, pancreatitis, skeletal muscle effects. Withdraw treatment if no adequate response after 2 mth of treatment at max recommended dose. Lactation: Unknown if excreted in breast milk; not recommended

Pregnancy-Lactation

Pregnancy Limited available data with fenofibrate use in pregnant women are insufficient to determine a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes Animal data In animal reproduction studies, no evidence of embryo-fetal toxicity was observed with oral administration in rats and rabbits during organogenesis at doses less than or equivalent to the maximum recommended clinical dose of 120 mg daily, based on body surface area (mg/m2) Adverse reproductive outcomes occurred at higher doses in presence of maternal toxicity; drug should be used during pregnancy only if potential benefit justifies potential risk to fetus Lactation There is no available information on presence of drug in human milk, effects on the breastfed infant, or on milk production; drug is present in milk of rats, and likely to be present in human milk; because of potential for serious adverse reactions in breastfed infants, such as disruption of infant lipid metabolism, women should not breastfeed during treatment and for 5 days after final dose

Interactions

Decreased absorption w/ bile acid sequestrants (e.g. colestyramine). May increase risk of ciclosporin-induced nephrotoxicity. Increased risk of muscle toxicity w/ HMG-CoA reductase inhibitors (e.g. simvastatin). May increase risk of bleeding w/ oral anticoagulants.

Adverse Effects

Side effects of Fenofibrate : 1-10% Abdominal pain (4.6%), Back pain (3.4%), Increased AST (3.4%), Headache (3.2%), Increased ALT (3%), Increased CPK (3%), Nausea (2.3%), Constipation (2.1%) Potentially Fatal: Hepatitis, cholecystitis.

Mechanism of Action

Fenofibrate, a fibric acid derivative, lowers plasma triglyceride by activating lipoprotein lipase thus increasing catabolism of VLDL w/ consequent increase in HDL levels.

Note

FENOGAL 200 mg Capsule, Hard manufactured by BENSON PHARMACEUTICALS. Its generic name is Fenofibrate. FENOGAL is availble in Saudi Arabia. Farmaco SA drug index information on FENOGAL Capsule, Hard is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.

Some other brands of Fenofibrate :

Capsule

TRIX ^{200 mg}

Jordan Sweden Medical and Sterilization Company

Film-coated Tablet

LIPANTHYL ^{145 mg}

Abbott Laboratories GmbH

Hetero Labs Limited Unit – V

Film-coated Tablet

Lipofirate ^{48 mg}

Hetero Labs Limited Unit – V